Correlation of serum omentin-1 level with clinical features and major adverse cardiac and cerebral events in patients undergoing continuous ambulatory peritoneal dialysis

References

• Ammirati AL. Chronic kidney disease. Rev Assoc Med Bras (1992). 2020;66(Suppl 1):s03–s09.
   PubMedGoogle Scholar
• Thurlow JS, Joshi M, Yan G, et al. Global epidemiology of end-stage kidney disease and disparities in kidney replacement therapy. Am J Nephrol. 2021;52(2):98–107.
   PubMed Web of Science ®Google Scholar
• Zhang L, Zuo L. Current burden of end-stage kidney disease and its future trend in China. Clin Nephrol. 2016;86(13):27–28.
   PubMedGoogle Scholar
• Braun MM, Khayat M. Kidney disease: end-Stage renal disease. FP Essent. 2021;509:26–32.
   PubMedGoogle Scholar
• Mohnen SM, van Oosten MJM, Los J, et al. Healthcare costs of patients on different renal replacement modalities – Analysis of Dutch health insurance claims data. PLOS One. 2019;14(8):e0220800.
   PubMed Web of Science ®Google Scholar
• Liu S, Tang X, Li X, et al. Efficacy of continuous ambulatory peritoneal dialysis combined with hemodialysis versus single hemodialysis in patients with end-stage renal disease. Am J Transl Res. 2021;13:10485–10492.
   PubMed Web of Science ®Google Scholar
• Zhang L, Guo Y, Ming H. Effects of hemodialysis, peritoneal dialysis, and renal transplantation on the quality of life of patients with end-stage renal disease. Rev Assoc Med Bras (1992). 2020;66(9):1229–1234.
   PubMed Web of Science ®Google Scholar
• Wang Y, Liu C, Wei W, et al. Predictive value of circulating coagulation related microRNAs expressions for major adverse cardiac and cerebral event risk in patients undergoing continuous ambulatory peritoneal dialysis: a cohort study. J Nephrol. 2020;33(1):157–165.
   PubMed Web of Science ®Google Scholar
• Liu D, Zhou S, Mao H. MicroRNA-497/fibroblast growth factor-23 axis, a predictive indictor for decreased major adverse cardiac and cerebral event risk in end-stage renal disease patients who underwent continuous ambulatory peritoneal dialysis. J Clin Lab Anal. 2020;34(6):e23220.
   PubMed Web of Science ®Google Scholar
• Wang H, Xu J, Wu X, et al. Longitudinal change in microRNA-130a expression and its correlation with the risk of developing major adverse cardiovascular and cerebral events in patients undergoing continuous ambulatory peritoneal dialysis. J Clin Lab Anal. 2021;35(12):e24039.
   PubMed Web of Science ®Google Scholar
• Watanabe T, Watanabe-Kominato K, Takahashi Y, et al. Adipose tissue-derived omentin-1 function and regulation. Compr Physiol. 2017;7:765–781.
   PubMed Web of Science ®Google Scholar
• Zhao A, Xiao H, Zhu Y, et al. Omentin-1: a newly discovered warrior against metabolic related diseases. Expert Opin Ther Targets. 2022;26(3):275–289.
   PubMed Web of Science ®Google Scholar
• Christodoulatos GS, Antonakos G, Karampela I, et al. Circulating omentin-1 as a biomarker at the intersection of postmenopausal breast cancer occurrence and cardiometabolic risk: an observational cross-sectional study. Biomolecules. 2021;11(11):1609.
   PubMed Web of Science ®Google Scholar
• Tan YL, Zheng XL, Tang CK. The protective functions of omentin in cardiovascular diseases. Clin Chim Acta. 2015;448:98–106.
   PubMed Web of Science ®Google Scholar
• Narumi T, Watanabe T, Kadowaki S, et al. Impact of serum omentin-1 levels on cardiac prognosis in patients with heart failure. Cardiovasc Diabetol. 2014;13:84.
   PubMed Web of Science ®Google Scholar
• Wang J, Zhuo X, Jiang Z. Omentin-1 circulating levels as predictor of heart diseases: a systematic review and meta-analysis. Rev Assoc Med Bras (1992). 2022;68(4):542–548.
   PubMed Web of Science ®Google Scholar
• Bai P, Abdullah F, Lodi M, et al. Association between coronary artery disease and plasma omentin-1 levels. Cureus. 2021;13(8):e17347.
   PubMed Web of Science ®Google Scholar
• Saely CH, Leiherer A, Muendlein A, et al. High plasma omentin predicts cardiovascular events independently from the presence and extent of angiographically determined atherosclerosis. Atherosclerosis. 2016;244:38–43.
   PubMed Web of Science ®Google Scholar
• Yao C, Zhou L, Huang Q. The occurrence and potential predictive factors of major adverse cardiac and cerebral events in end-stage renal disease patients on continuous ambulatory peritoneal dialysis: a prospective cohort study. Medicine. 2021;100(10):e24616.
   PubMed Web of Science ®Google Scholar
• Tekce H, Tekce BK, Aktas G, et al. Serum omentin-1 levels in diabetic and nondiabetic patients with chronic kidney disease. Exp Clin Endocrinol Diabetes. 2014;122(8):451–456.
   PubMed Web of Science ®Google Scholar
• Song J, Zhang H, Sun Y, et al. Omentin-1 protects renal function of mice with type 2 diabetic nephropathy via regulating miR-27a-Nrf2/Keap1 axis. Biomed Pharmacother. 2018;107:440–446.
   PubMed Web of Science ®Google Scholar
• Galindo RJ, Beck RW, Scioscia MF, et al. Glycemic monitoring and management in advanced chronic kidney disease. Endocr Rev. 2020;:41:756–774.
   PubMed Web of Science ®Google Scholar
• Skubala A, Zywiec J, Zelobowska K, et al. Continuous glucose monitoring system in 72-hour glucose profile assessment in patients with end-stage renal disease on maintenance continuous ambulatory peritoneal dialysis. Med Sci Monit. 2010;16: CR75–83.
   PubMed Web of Science ®Google Scholar
• Bindroo S, Quintanilla Rodriguez BS, Challa HJ. Renal failure. Treasure Island (FL): StatPearls;2022.
   Google Scholar
• Tan BK, Adya R, Farhatullah S, et al. Omentin-1, a novel adipokine, is decreased in overweight insulin-resistant women with polycystic ovary syndrome: ex vivo and in vivo regulation of omentin-1 by insulin and glucose. Diabetes. 2008;57(4):801–808.
   PubMed Web of Science ®Google Scholar
• Zabetian-Targhi F, Mirzaei K, Keshavarz SA, et al. Modulatory role of omentin-1 in inflammation: cytokines and dietary intake. J Am Coll Nutr. 2016;35(8):670–678.
   PubMed Web of Science ®Google Scholar
• Feng SK, Chen TH, Li HM, et al. Deficiency of omentin-1 leads to delayed fracture healing through excessive inflammation and reduced CD31(hi)Emcn(hi) vessels. Mol Cell Endocrinol. 2021;534:111373.
   PubMed Web of Science ®Google Scholar
• Cabral VLF, Wang F, Peng X, et al. Omentin-1 promoted proliferation and ameliorated inflammation, apoptosis, and degeneration in human nucleus pulposus cells. Arch Gerontol Geriatr. 2022;102:104748.
   PubMedGoogle Scholar
• Zhang RX, Zhang X, Zhang BL, et al. Expression of adipokines in children with primary nephrotic syndrome and its association with hyperlipidemia. Zhongguo Dang Dai Er Ke Za Zhi. 2021;23:828–834.
   PubMedGoogle Scholar
• Johansen KL, Chertow GM, Foley RN, et al. US renal data system 2020 annual data report: epidemiology of kidney disease in the United States. Am J Kidney Dis. 2021;77(4 Suppl 1):A7–A8.
   PubMed Web of Science ®Google Scholar
• Watanabe K, Watanabe R, Konii H, et al. Counteractive effects of omentin-1 against atherogenesisdagger. Cardiovasc Res. 2016;110(1):118–128.
   PubMed Web of Science ®Google Scholar
• Yamawaki H, Kuramoto J, Kameshima S, et al. Omentin, a novel adipocytokine inhibits TNF-induced vascular inflammation in human endothelial cells. Biochem Biophys Res Commun. 2011;408(2):339–343.
   PubMed Web of Science ®Google Scholar
• Power A, Brown E. Optimising treatment of end-stage renal disease in the elderly. Nephron Clin Pract. 2013;124(3-4):202–208.
   PubMedGoogle Scholar
• Liu J, Rosner MH. Lipid abnormalities associated with end-stage renal disease. Semin Dial. 2006;19(1):32–40.
   PubMed Web of Science ®Google Scholar
• Ducloux D, Bresson-Vautrin C, Kribs M, et al. C-reactive protein and cardiovascular disease in peritoneal dialysis patients. Kidney Int. 2002;62(4):1417–1422.
   PubMed Web of Science ®Google Scholar
• Jin M, Yang F, Yang I, et al. Uric acid, hyperuricemia and vascular diseases. Front Biosci. 2012;17(2):656–669.
   PubMedGoogle Scholar
• Casula M, Colpani O, Xie S, et al. HDL in atherosclerotic cardiovascular disease: in search of a role. Cells. 2021;10(8):1869.
   PubMed Web of Science ®Google Scholar